Biogen highlights potential of felzartamab

Biogen (BIIB) will host a virtual investor seminar focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to target CD38 for a range of immune-mediated diseases. “We have made important progress to support our long-term growth objective, build a strong portfolio with momentum from our recently launched products, and advance an innovative and compelling pipeline,” said Christopher Viehbacher, President and Chief Executive Officer at Biogen. “We are particularly excited about the addition of felzartamab, which gives us the potential to deliver novel treatments across a range of immune-mediated diseases, beginning with three rare kidney diseases.” Biogen is initiating three pivotal Phase 3 studies of felzartamab across rare kidney indications in 2025, with first readout expected in 2027.